» Articles » PMID: 10224276

Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism

Overview
Journal J Exp Med
Date 1999 May 4
PMID 10224276
Citations 608
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently shown that expression of the enzyme indoleamine 2, 3-dioxygenase (IDO) during murine pregnancy is required to prevent rejection of the allogeneic fetus by maternal T cells. In addition to their role in pregnancy, IDO-expressing cells are widely distributed in primary and secondary lymphoid organs. Here we show that monocytes that have differentiated under the influence of macrophage colony-stimulating factor acquire the ability to suppress T cell proliferation in vitro via rapid and selective degradation of tryptophan by IDO. IDO was induced in macrophages by a synergistic combination of the T cell-derived signals IFN-gamma and CD40-ligand. Inhibition of IDO with the 1-methyl analogue of tryptophan prevented macrophage-mediated suppression. Purified T cells activated under tryptophan-deficient conditions were able to synthesize protein, enter the cell cycle, and progress normally through the initial stages of G1, including upregulation of IL-2 receptor and synthesis of IL-2. However, in the absence of tryptophan, cell cycle progression halted at a mid-G1 arrest point. Restoration of tryptophan to arrested cells was not sufficient to allow further cell cycle progression nor was costimulation via CD28. T cells could exit the arrested state only if a second round of T cell receptor signaling was provided in the presence of tryptophan. These data reveal a novel mechanism by which antigen-presenting cells can regulate T cell activation via tryptophan catabolism. We speculate that expression of IDO by certain antigen presenting cells in vivo allows them to suppress unwanted T cell responses.

Citing Articles

Myeloid cells: key players in tumor microenvironments.

Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .

PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.


Comprehensive single-cell analysis of triple-negative breast cancer based on cDC1 immune-related genes: prognostic model construction and immunotherapy potential.

Huang L, Liu Y, Shi Y, Sun Q, Li H, Sun C Discov Oncol. 2025; 16(1):206.

PMID: 39969635 PMC: 11839968. DOI: 10.1007/s12672-025-01929-1.


Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response.

Gorria T, Sierra-Boada M, Rojas M, Figueras C, Marin S, Madurga S Cancers (Basel). 2025; 17(3).

PMID: 39941865 PMC: 11815897. DOI: 10.3390/cancers17030498.


Identification of T cell dysfunction molecular subtypes and exploration of potential immunotherapy targets in BRAF V600E-mutant colorectal cancer.

Gu T, Qi H, Wang J, Sun L, Su Y, Hu H Discov Oncol. 2025; 16(1):163.

PMID: 39934467 PMC: 11813846. DOI: 10.1007/s12672-025-01930-8.


Advances and prospects of cell-penetrating peptides in tumor immunotherapy.

Yang D, Liu B, Sha H Sci Rep. 2025; 15(1):3392.

PMID: 39870681 PMC: 11772771. DOI: 10.1038/s41598-025-86130-8.


References
1.
Munn D, Zhou M, Attwood J, Bondarev I, Conway S, Marshall B . Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281(5380):1191-3. DOI: 10.1126/science.281.5380.1191. View

2.
Laliberte J, Yee A, Xiong Y, Mitchell B . Effects of guanine nucleotide depletion on cell cycle progression in human T lymphocytes. Blood. 1998; 91(8):2896-904. View

3.
Fazekas de St Groth B . The evolution of self-tolerance: a new cell arises to meet the challenge of self-reactivity. Immunol Today. 1998; 19(10):448-54. DOI: 10.1016/s0167-5699(98)01328-0. View

4.
Oehen S . Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division. J Immunol. 1998; 161(10):5338-46. View

5.
Knox W, MEHLER A . The adaptive increase of the tryptophan peroxidase-oxidase system of liver. Science. 1951; 113(2931):237-8. DOI: 10.1126/science.113.2931.237. View